BRIEF published on 03/27/2026 at 07:35, 2 days 4 hours ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 2 days 4 hours ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 6 days 2 hours ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 11 days 1 hour ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
PRESS RELEASE published on 03/18/2026 at 10:15, 11 days 2 hours ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 19 days 3 hours ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 19 days 3 hours ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 20 days 4 hours ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
BRIEF published on 03/09/2026 at 07:35, 20 days 4 hours ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
PRESS RELEASE published on 03/09/2026 at 07:30, 20 days 4 hours ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
Published on 03/28/2026 at 01:00, 1 day 10 hours ago Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 1 day 10 hours ago Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:45, 1 day 12 hours ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 03/27/2026 at 22:30, 1 day 12 hours ago Usha Resources Completes Extended Induced Polarization Survey at the Southern Arm Property
Published on 03/28/2026 at 10:05, 1 day 2 hours ago Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 3 hours ago Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 9 hours ago EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 1 day 13 hours ago Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 20:08, 1 day 15 hours ago EQS-Adhoc: CECONOMY AG: Information on the ongoing public takeover process – uncertainty regarding FDI clearance in Austria
Published on 03/27/2026 at 18:52, 1 day 16 hours ago Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:40, 1 day 16 hours ago 2026 share capital increase reserved for members of the Saint-Gobain Group employee savings plan
Published on 03/27/2026 at 17:53, 1 day 17 hours ago Publication of Carrefour's 2025 Universal Registration Document
Published on 03/27/2026 at 17:45, 1 day 17 hours ago PUBLICATION OF THE UNIVERSAL REGISTRATION DOCUMENT FISCAL YEAR 2025
